Literature DB >> 7517330

Evidence that nitric oxide is an endogenous antiangiogenic mediator.

E Pipili-Synetos1, E Sakkoula, G Haralabopoulos, P Andriopoulou, P Peristeris, M E Maragoudakis.   

Abstract

1. The involvement of nitric oxide (NO) in the regulation of angiogenesis was examined in the in vivo system of the chorioallantoic membrane (CAM) of the chick embryo and in the matrigel tube formation assay. 2. Sodium nitroprusside (SNP) (0.37-28 nmol/disc), which releases NO spontaneously, caused a dose-dependent inhibition of angiogenesis in the CAM in vivo and reversed completely the angiogenic effects of alpha-thrombin (6.7 nmol/disc) and the protein kinase C (PKC) activator 4-beta-phorbol-12-myristate-13-acetate (PMA) (0.97 nmol/disc). In addition, SNP (28 x 10(-6) M) stimulated the release of guanosine 3'-5'-cyclic monophosphate (cyclic GMP) from the CAM in vitro. 3. In the matrigel tube formation assay, an in vitro assay of angiogenesis, both SNP (1-3 x 10(-6) M) and the cell permeable cyclic GMP analogue, Br-cGMP (0.3-1.0 x 10(-3) M) reduced tube formation. 4. The inhibitors of NO synthase, NG-monomethyl-L-arginine (L-NMMA) (3.8-102 nmol/disc) and NG-nitro-L-arginine methylester (L-NAME) (1.3-34.2 nmol/disc) stimulated angiogenesis in the CAM in vivo, in a dose-dependent fashion. D-NMMA and D-NAME on the other hand had no effect on angiogenesis in this system. 5. L-Arginine (10.9 nmol/disc), although it had a modest antiangiogenic effect by itself, was capable of abolishing the angiogenic effects of L-NMMA (34.2 nmol/disc) and of L-NAME (3.8 nmol/disc). 6. Dexamethasone, an inhibitor of the induction of NO synthase, at 0.2-116.1 nmol/disc, stimulated angiogenesis in the CAM, whereas at 348.4-1161 nmol/disc it inhibited this process. Combination of 38.7 nmol/disc dexamethasone with L-NAME (9.3 nmol/disc) resulted in a potentiation of the angiogenic effect of the former. It appears therefore that both the constitutive and the inducible NO synthase may contribute to the NO-mediated inhibition of angiogenesis. 7. Superoxide dismutase (SOD), which prevents the destruction of NO, at 300 i.u./disc had a modest antiangiogenic effect in the CAM, by itself. In addition, SOD, prevented alpha-thrombin (6.7 nmol/disc) and PMA (0.97 nmol/disc) from stimulating angiogenesis in the CAM.8. These results suggest that NO may be an endogenous antiangiogenic molecule of pathophysiological importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517330      PMCID: PMC1910111          DOI: 10.1111/j.1476-5381.1994.tb14822.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  Isoforms of nitric oxide synthase. Characterization and purification from different cell types.

Authors:  U Förstermann; H H Schmidt; J S Pollock; H Sheng; J A Mitchell; T D Warner; M Nakane; F Murad
Journal:  Biochem Pharmacol       Date:  1991-10-24       Impact factor: 5.858

2.  Immunovascular communication: activation and deactivation of murine endothelial cell nitric oxide synthase by cytokines.

Authors:  M Schneemann; G Schoedon; K Frei; A Schaffner
Journal:  Immunol Lett       Date:  1993-02       Impact factor: 3.685

3.  Glucocorticoids inhibit the induction of nitric oxide synthase and the related cell damage in adenocarcinoma cells.

Authors:  K J O'Connor; S Moncada
Journal:  Biochim Biophys Acta       Date:  1991-10-21

4.  Nitric oxide is involved in the regulation of angiogenesis.

Authors:  E Pipili-Synetos; E Sakkoula; M E Maragoudakis
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Thrombin promotes angiogenesis by a mechanism independent of fibrin formation.

Authors:  N E Tsopanoglou; E Pipili-Synetos; M E Maragoudakis
Journal:  Am J Physiol       Date:  1993-05

6.  Evidence for the involvement of both ATP and nitric oxide in non-adrenergic, non-cholinergic inhibitory neurotransmission in the rabbit portal vein.

Authors:  A L Brizzolara; R Crowe; G Burnstock
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

7.  Platelet activation by diacylglycerol or ionomycin is inhibited by nitroprusside.

Authors:  M G Doni; R Deana; E Padoin; M Ruzzene; A Alexandre
Journal:  Biochim Biophys Acta       Date:  1991-09-24

8.  [Inhibition of neovascularization and tumor growth by dexamethasone].

Authors:  O Nakamura; K Ueki; T Hibi; N Shitara; M Matsutani; K Takakura; T Oikawa
Journal:  No To Shinkei       Date:  1992-01

9.  Steroid inhibition of neural microvessel morphogenesis in vitro: receptor mediation and astroglial dependence.

Authors:  J E Wolff; J Laterra; G W Goldstein
Journal:  J Neurochem       Date:  1992-03       Impact factor: 5.372

Review 10.  Thrombin structure and function: why thrombin is the primary target for antithrombotics.

Authors:  J W Fenton; F A Ofosu; D G Moon; J M Maraganore
Journal:  Blood Coagul Fibrinolysis       Date:  1991-02       Impact factor: 1.276

View more
  24 in total

1.  Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro.

Authors:  A Papapetropoulos; K M Desai; R D Rudic; B Mayer; R Zhang; M P Ruiz-Torres; G García-Cardeña; J A Madri; W C Sessa
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Authors:  Tanyel Kiziltepe; Kenneth C Anderson; Jeffery L Kutok; Lee Jia; Kenneth M Boucher; Joseph E Saavedra; Larry K Keefer; Paul J Shami
Journal:  J Pharm Pharmacol       Date:  2010-01       Impact factor: 3.765

3.  Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats.

Authors:  F J Dowell; D Henrion; M Duriez; J B Michel
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

4.  Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.

Authors:  M Ziche; L Morbidelli; R Choudhuri; H T Zhang; S Donnini; H J Granger; R Bicknell
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

5.  Endogenously produced nitric oxide inhibits endothelial cell growth as demonstrated using novel antisense cell lines.

Authors:  J E Cartwright; A P Johnstone; G S Whitley
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

6.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.

Authors:  A Papapetropoulos; G García-Cardeña; J A Madri; W C Sessa
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

7.  Effects of low dose ionizing radiation on murine chronic granulomatous tissue.

Authors:  G Hildebrandt; M P Seed; C N Freemantle; C A Alam; P R Colville-Nash; K R Trott
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

8.  Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate.

Authors:  E Pipili-Synetos; A Papageorgiou; E Sakkoula; G Sotiropoulou; T Fotsis; G Karakiulakis; M E Maragoudakis
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.

Authors:  T Murohara; T Asahara; M Silver; C Bauters; H Masuda; C Kalka; M Kearney; D Chen; J F Symes; M C Fishman; P L Huang; J M Isner
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

10.  CDC-derived extracellular vesicles reprogram inflammatory macrophages to an arginase 1-dependent proangiogenic phenotype.

Authors:  Kyle I Mentkowski; Asma Mursleen; Jonathan D Snitzer; Lindsey M Euscher; Jennifer K Lang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-04-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.